by Vora Corporate Finance | Apr 16, 2025 | Insights, Private Equity & IPO
Transaction: DCDC Kidney Care, which operates dialysis centers under the DCDC Kidney Care brand, has secured an investment of ₹150 crore from Singapore-based ABC Impact, the Asia-focused impact investor backed by Temasek. About DCDC Kidney Care: Founded in 2009, DCDC...
by Vora Corporate Finance | Apr 16, 2025 | Insights, Merger & Acquisitions
Transaction: Zydus Lifesciences Limited has entered into exclusive negotiations to purchase a controlling stake of 85.6% in France-based Amplitude Surgical SA for a deal valued at €256.8 million (over ₹2,400 crore). Zydus will file a mandatory cash tender offer for...
by Vora Corporate Finance | Apr 16, 2025 | Insights
There were No main board IPOs in March 2025 against 04 main board IPOs in February 2025. There were 07 SME IPOs in March 2025 as against 06 SME IPOs in February 2025. After heightened activity in 2024, there has been a slowdown in new listings, with no main-board...
by Vora Corporate Finance | Apr 16, 2025 | Insights
The BSE Sensex closed at 77,414.92 gaining by 5.76% and the Nifty 50 closed at 23,519.35 gaining by 6.30% in March 2025, pausing after a six-session rally that erased their 2025 losses, as uncertainty over U.S. reciprocal import tariffs kept investors cautious....
by Vora Corporate Finance | Apr 16, 2025 | Insights
US Tariff War II: The global economy is facing increased uncertainty due to trade tensions, market volatility, and geopolitical risks. The US President is intensifying this instability by initiating trade wars with both allies and adversaries, using tariffs to counter...
